Jonathan Mizrahi, MD: Long-Term OS Outcomes Across Subgroups in the HIMALAYA Trial
Dr. Mizrahi discusses 5- and 6-year overall survival (OS) data from the HIMALAYA trial, which examined the STRIDE regimen (durvalumab + tremelimumab) compared to sorafenib for patients with unresectable hepatocellular carcinoma (uHCC). Long-term OS outcomes among patient subgroups, including viral and nonviral disease etiology subgroups, are explored.
Topics covered:
- 5- and 6-year OS data from the HIMALAYA trial
- Long-term survival for patients with uHCC across subgroups
- How patients with nonviral disease etiology benefit from the STRIDE regimen
